TNFSF13B and myeloid sarcoma: The same results were obtained when MS patients MAP0106c121–132 negative were tested (Fig. 3B) where an higher BAFF serum level was found in MS patients MAP negative in comparison to MS patients MAP0106c121–132 positive (p = 0.0088), MS patients MAP0106c121–132 positive and negative under MP treatment (p = 0.0009 and p = 0.0021 respectively; Fig. 3B).